A New Hope on Organ Transplants for People With HIV

People with HIV are now living healthier, longer lives thanks to advances in antiretroviral therapy, but they can still have chronic diseases like diabetes and hypertension. Eventually, they might need organ replacements, like kidneys, but this group of people has been at a disadvantage.

Patients with HIV have been known to receive lower priority on waitlists given the shortage of organs and misconceptions about the patients’ ability to receive them. But what if we could increase the pool of available organs by allowing the use of organs from donors with HIV for recipients with HIV?

A new milestone was achieved in a first-of-its-kind study in the United States in which Mount Sinai was a major player. The HOPE study, published in The New England Journal of Medicine, showed that not only are kidney transplants from HIV+ donors safe and effective, they are just as much so as transplants from HIV- donors.

“It had been illegal, by federal law, to use HIV+ organs,” says Sander Florman, MD, Director of the Recanati/Miller Transplantation Institute at Mount Sinai and an author of the paper. “Prior to the HOPE Act signed by then-President Obama, organs with HIV had to be discarded. But if we can show it is safe to use organs from people with HIV, why not use them, so that HIV+ people can get transplanted quicker?”

“Eventually, the goal of this study is to move HIV-to-HIV kidney transplants out of just research and into a standard of care,” says Meenakshi Rana, MD, Associate Professor of Medicine (Infectious Diseases), Icahn School of Medicine at Mount Sinai, and an author of the paper. “This has larger implications not just for people with HIV, but for everyone who’s on a waitlist—if a person with HIV can receive an organ faster from a donor with HIV, then everyone on the list also moves up.”

Drs. Florman and Rana discuss the importance of the HOPE study, how it could destigmatize organ transplants for people with HIV, and future impacts.

What’s the history of organ transplantation for people who are HIV+?

In the past, people with HIV were considered not medically suitable for organ transplants. It was thought that the immune-suppressing drugs required to prevent organ rejection might cause the HIV to develop into AIDS, says Dr. Florman.

In the late 1990s, Mount Sinai showed that it was possible to do a living liver donation to a patient with HIV. “It was extremely controversial,” says Dr. Florman. “At the time, nobody was doing HIV transplants. And second of all, very few centers in the country were doing living-donor liver transplants.”

Sandy Florman, MD, Director of the Recanati/Miller Transplantation Institute at Mount Sinai (left) and Meenakshi Rana, MD, Associate Professor of Medicine, Infectious Diseases (right).

What is the current law on use of organs from donors with HIV?

In regulations dating to 1988, it was made illegal to transplant or even study organs from donors with HIV. In 2013, President Obama signed the HIV Organ Policy Equity (HOPE) Act, which lifted the research ban.

On November 26, 2024, the U.S. Department of Health and Human Services announced a final rule stating kidney and liver transplants involving donors and recipients with HIV no longer need to be done under the auspices of a clinical trial. The decision was motivated by evidence from studies enabled by the HOPE Act that showed such procedures were safe and effective.

In the 2000s, Mount Sinai participated in another trial that showed it was possible to transplant kidneys from donors without HIV to recipients with HIV—a trial that was the predecessor to the HOPE study.

However, people with HIV faced more than just medical skepticism—they also faced social stigma.

What does having an undetectable HIV load mean?

Having an undetectable load, or simply being undetectable, means HIV levels in a person are so low that they cannot transmit the virus to another person sexually. This is typically achieved through antiretroviral therapy.

“Even with the advent of the medications, where your HIV can be well controlled and you could live a normal life, there is stigma among some medical professionals about getting a needlestick or getting splashed in the eye with blood,” says Dr. Florman. “The reality is that part of the criteria for doing these transplants is that the candidates need to have well-controlled HIV, even undetectable viral load. And so the risk of getting HIV from a needlestick or a splash is actually very low, although not zero.”

What were the HOPE study results?

The HOPE study transplanted 198 kidneys into recipients with HIV. Half of those kidneys were from donors with HIV and the other half from donors without. Mount Sinai was the largest enroller of the trial, transplanting 55 patients.

  • There was no significant difference in outcomes between both groups, including overall survival at one year and three years, survival without graft loss at one year and three years, and rejection at one year.
  • Adverse events, infections, and complications were similar between both groups, and any HIV-related infection events were able to be treated.

What impacts could this study have?

“Even though we’ve had previous findings that people with HIV could receive transplants, historically, people with HIV have had longer wait times in terms of access to an organ, and higher mortality rates,” says Dr. Rana. “So one of the huge implications of this study is that it could really reduce the wait time of access to organ transplantation for people with HIV, and that’s really important for reducing disparities in transplant.”

That goal is one step closer to becoming reality. On November 26, 2024, the U.S. Department of Health and Human Services announced a final rule stating that after a decade of studies enabled by the HOPE Act, kidney and liver transplants between donors and recipients with HIV are now permitted, and no longer have to be done as clinical trials.

This announcement will hopefully encourage organ procurement organizations (OPOs) to be more inclusive of donors with HIV. “Some OPOs have been good and pursued donors with HIV. Others have not been interested for a variety of reasons. Hopefully, as more HIV patients are able to access transplants, these OPOs would follow the demand and seek more donors with HIV,” says Dr. Florman.

Additionally, the study could expand awareness among patients with HIV and providers that access to life-saving transplantation is more a possibility than ever, says Dr. Rana.

Does this mean people with HIV should consider becoming donors?

“I would definitely want to encourage people with HIV to become donors,” says Dr. Rana. “This would help destigmatize what it means to be a person living with HIV.”

“The patients we helped transplant have always been very grateful, especially because other centers often wouldn’t offer them the procedure,” says Dr. Florman. “But I was surprised that people with HIV who don’t need transplants are grateful that they can now be organ donors. Because now they feel a sense of pride in the idea that they, too, can be organ donors and help save other lives.”

From Brain Scans to Wearables, Learn More About the Research at Mount Sinai’s New AI Center

The Mount Sinai Health System has been an early adopter of artificial intelligence (AI) in improving patient care and health over the past few years, innovating in various clinical areas such as in imaging and patient monitoring. Now, the Health System is doubling on its investment in the field, and is opening the Hamilton and Amabel James Center for Artificial Intelligence and Human Health on November 25, a 12-story, 65,000-square-foot facility at 3 East 101st Street. The facility aims to organize Mount Sinai’s artificial intelligence (AI) efforts under one roof, to facilitate collaboration and innovation.

“Mount Sinai sees artificial intelligence and machine learning as key to our continued successes in making critical discoveries in science and in advancing medicine,” says David Reich, MD, President of The Mount Sinai Hospital.

The co-location of data scientists with the basic science and clinical scientists on the campus shared by the Icahn School of Medicine at Mount Sinai and The Mount Sinai Hospital is a strategic decision to create a community of clinical, basic, and data scientists that interact seamlessly.

The new building houses Mount Sinai’s core AI facilities: the Windreich Department of Artificial Intelligence and Human Health; the Hasso Plattner Institute for Digital Health at Mount Sinai; the Institute for Genomic Health; the Mount Sinai BioMedical Engineering and Imaging Institute; and the Charles Bronfman Institute for Personalized Medicine.

Exterior of the Hamilton and Amabel James Center for Artificial Intelligence and Human Health.

Investing in AI is key to Mount Sinai’s commitment to patient health. “Science and medicine are advancing rapidly and artificial intelligence is the key to scaling our ability to help our staff be more effective in creating better outcomes and enhancing safety in multiple clinical domains and to speed scientific discovery,” says Dr. Reich.

What do the core facilities do, and what are some of the research activities going on inside? Click on each button to find out more.

Windreich Department of Artificial Intelligence and Human Health
Hasso Plattner Institute for Digital Health at Mount Sinai
Institute for Genomic Health
Mount Sinai BioMedical Engineering and Imaging Institute
The Charles Bronfman Institute for Personalized Medicine

The Department was founded more than two years ago. Its inaugural Chair, Thomas Fuchs, Dr.sc., Dean for Artificial Intelligence, set a goal of designing an “intelligent fabric”—a platform containing various AI tools and services that can be easily integrated into clinical applications at hospitals within the Health System. This centralized platform would help clinicians get a holistic view of the patient, which not only helps on the diagnostic side, but also for treatment decisions, better follow-up, and better prevention of disease, says Dr. Fuchs.

The Department has more than 80 faculty members, spanning clinicians, basic scientists, computer scientists, and engineers. In addition to creating AI tools for the Health System, it hosts the annual New Wave of AI in Healthcare conference to share findings with Mount Sinai researchers and other institutions around the country. Research areas include computational pathology and machine learning in chronic disease characterization and management. Some activities include:

  • Oncology: In collaboration with The Tisch Cancer Institute, an ongoing project involves the development of computational biomarkers for cancer, which could be used to predict patient outcomes and recommend treatment options or clinical trials for patients.
  • Neurology: The Department is involved in the 10,000 Brains Project, a philanthropic initiative that uses AI in the fight against neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. It intends to digitize neuropathology slides of brains across diverse populations, aiming to uncover underlying mechanisms and shed light on diagnostic and treatment options in the future.
  • Pathology: Team members are building what could be considered the largest academic foundation model in pathology. It comprises billions of images from millions of digitized slides to provide data and information about the microscopic world. This data could be used as a foundation for AI applications to build biomarkers, create predictive models, or answer questions about cancer and tissues.

Learn more about the Windreich Department of Artificial Intelligence and Human Health

The institute was formed in 2019 through a collaboration with the Hasso Plattner Institute for Digital Engineering in Potsdam, Germany. With a focus on software and digital health solutions, the Institute builds computational frameworks and architectures for rapid scientific discovery, and mobile applications that integrate health data from patients via wearables. With more than 12 concurrent ongoing studies, some key projects include:

  • AI-Ready Mount Sinai (AIR·MS): Patient data, such as scans or clinical reports, can often be siloed in separate departments. AIR·MS is a cloud-based platform that integrates Mount Sinai patient data into a consistent format. This platform allows researchers access to information about Mount Sinai’s 12 million patients to build out AI applications at scale or to conduct research.
  • Ehive: A platform involving a mobile application, available on the Apple App Store or Google Play, that conducts digital health studies. Participants answer questions on the app and provide other health information via wearables, such as an Apple Watch, for the study’s duration. Ehive helps researchers understand complex diseases and wellness.

Learn more about the Hasso Plattner Institute for Digital Health at Mount Sinai

Genomics involves the study of genes and genetic material and how they might affect health. Led by Eimear Kenny, PhD, Director of the Institute, teams use AI to analyze and characterize the vast information from DNA and genetic material, collected from biobanks such as the BioMe® and Mount Sinai Million Health Discovery programs, to examine the health impact of disease-associated genes and variants in real-world settings. Some key focus areas include:

  • Genomic discovery: Teams are involved in large-scale projects that infer population history through genetic sequencing. These studies provide information about how genetic diversity has changed throughout history, evolution, and disease. Ongoing projects vary in scope from the local population in East Harlem in Manhattan to continental populations in North and South America.
  • Medical genomics: With a better understanding of genetic data, researchers can infer the prevalence, clinical impact, and comorbidities associated with a particular variant. The institute is involved in the NYCKidSeq clinical trial, a collaboration between Mount Sinai, the New York Genome Center, and Montefiore Medical Center and its Albert Einstein College of Medicine, to find genetic causes of health problems in children. Other efforts look at the intersection of genomics and infectious diseases, screening, and electronic health records.

Learn more about the Institute for Genomic Health

With a team of more than 45 members and under the leadership of its Director, Zahi Fayad, PhD, the Institute works at the forefront of imaging, nanomedicine, and drug delivery, with a focus on brain, heart, and cancer research. The Institute has a track record with wearable innovations, but it is also making strides in AI-powered digital solutions. Some recent innovations include:

  • Warrior Watch: By applying AI to analyze heart rate and other variables collected via an Apple Watch, researchers developed a way to monitor and assess psychological states remotely without requiring the completion of mental health questionnaires. The study found the AI model to be predictive in identifying resilience or well-being states.
  • “Digital twin”: By computationally modeling pathway interactions of cells and organs, researchers at the institute have created essentially a “digital twin” of organs. This allows researchers to make predictions about gene expression and organ function, which in turn allow for better understanding of health and disease states.

Learn more about the Mount Sinai BioMedical Engineering and Imaging Institute

Spearheading the biobank programs, including the BioMe® and Mount Sinai Million Health Discovery programs, the Institute, guided by co-Directors Alexander Charney, MD, PhD, and Girish Nadkarni, MD, works closely with the Institute for Genomic Health and others to understand human disease through cohort studies. AI is the backbone for genetic sequencing to provide insight into how one’s genes might influence health, but also other factors including environmental and socioeconomic.

  • Mount Sinai Million Health Discoveries Program: This endeavor aims to carry out genetic sequencing of 1 million Mount Sinai patients in five years, and is considered one of the largest sequencing projects of its kind. With understanding of health at a local and population level, the program hopes not only to discover new therapeutics to treat and prevent disease, but also to integrate genomic profiling into routine clinical decision-making.
  • BioMe®: A vast, ongoing collection of de-identified data comprising information about DNA, plasma, clinical medical records, and questionnaire data, and large-scale genome-wide genotype and exome-chip data. Since its creation in 2019, the biobank has acquired information from more than 52,500 patients. The database allows genetic, epidemiologic, molecular, and genomic studies in many different fields, including inflammatory bowel disease, chronic kidney disease, cancer, allergic conditions, and more.

Learn more about The Charles Bronfman Institute for Personalized Medicine

Highlights From the European Committee for Treatment and Research in Multiple Sclerosis

Every year, the team from The Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai participates in the European Committee for Treatment and Research in Multiple Sclerosis Conference, one of the world’s largest gatherings focused on multiple sclerosis (MS) research and care. This event provides a platform for our physicians and researchers to contribute to discussions on the latest advancements and breakthroughs in the field, collaborate with global leaders, and bring back cutting-edge tools to improve the lives of our patients.

This year’s conference was hosted in Copenhagen, where the Mount Sinai team joined more than 8,500 researchers, clinicians, and people living with multiple sclerosis from 103 countries. Celebrating “40 years of dedication to MS research and treatment,” the event showcased advancements in understanding and managing the disease. Attendees attended keynote speeches, scientific presentations, and educational sessions, including a dedicated day for the patient community, emphasizing their vital role in ongoing MS research.

Robin Graney, Clinical Research Coordinator

One of the most notable developments discussed was the update to the McDonald Diagnostic Criteria for MS, presented by Xavier Montalban, MD, Chair of the Department of Neurology and Director of the Multiple Sclerosis Center of Catalonia at the Vall d’Hebron University Hospital. The revisions aim to improve the speed and accuracy of MS diagnoses, particularly in older adults and children.

The new criteria introduce additional diagnostic tools, including modern MRI imaging findings and blood biomarkers, which are designed to reduce the risk of misdiagnoses. These technologies will be widely introduced over the next couple of years, and new terms like “central vein sign” (CVS) and “paramagnetic rim lesions” (PRL) will enter the MS lexicon.

The initiative, supported by a diverse group of stakeholders, will be accompanied by a global education campaign to ensure the MS community understands these changes. From the Center, Fred Lublin, MD, and Aaron Miller, MD, serve on the McDonald Criteria committee.

Research presentations also highlighted promising treatment developments, including the investigational drug tolebrutinib, which showed a 31 percent delay in disability progression in secondary progressive MS in the HERCULES trial. Although concerns about liver safety were raised, the results indicate that tolebrutinib could represent a significant step forward for this group of patients.

Stephen Krieger, MD

The Center served as a trial site for the last four years, with Stephen Krieger, MD, serving as the site’s investigator. The Center is deeply grateful to the 10 patients at Mount Sinai who participated in the trial.

Other research discussed the benefits of high-dose vitamin D in reducing MS activity, while excitement also surrounded a series of upcoming trials studying CAR T-cell therapies, which are being explored for their potential to treat autoimmune diseases like MS.

Another key focus of the conference was on the importance of patient-centered care. Discussions emphasized aligning patient and clinician priorities during appointments to enhance care quality.

Also, the updated “Brain Health–Time Matters” report highlighted the essential role of MS specialist nurses, who provide crucial support and guidance. Disparities in access to specialist nursing care remain a concern globally, particularly in lower-income countries, underscoring the need for continued advocacy and improvement in MS care services worldwide.

What You Need to Know About Participating in Autism Research at Mount Sinai


Clinical research is critical to advance our understanding of the causes of neurodevelopmental disorders and to develop effective treatments. The Seaver Autism Center for Research and Treatment at Mount Sinai maintains an active clinical research portfolio with a variety of recruiting studies at any given time.

Individuals on the autism spectrum as well as those with certain related genetic syndromes may be eligible to participate. The Seaver Center’s Rare Disease Program studies Phelan-McDermid syndrome, ADNP syndrome, FOXP1 syndrome, and DDX3X syndrome. Areas of focus include biomarker discovery, natural history studies, and clinical trials.

In addition to valuable contributions to science, the Seaver Center team works hard to ensure study participation is an enjoyable and low stress experience. When reflecting on their experiences, Seaver Autism Center families often recall a sense of warmth and trust.

One parent, Sakia, felt touched by how happy her son is whenever her family arrives for a visit: “As soon as he walks in, he’s running in, running into rooms, and it doesn’t bother anybody. Everyone is very welcoming.”

Paige Siper, PhD

In this Q&A, Paige Siper, PhD, Chief Psychologist of the Seaver Center, explains how research studies are conducted, the benefits of participating, and how you or someone you know can get involved.

What happens at a research study visit?

Research visits include standardized assessments administered by the clinical research team. Our multidisciplinary team spans psychiatry, psychology, and neurology, including a robust training program of psychology and psychiatry students and fellows. For idiopathic autism studies, gold-standard diagnostic testing, including the Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) is administered to determine eligibility. For studies in genetic syndromes, results from genetic testing are reviewed to confirm eligibility. Most studies include cognitive and adaptive assessments. Results from clinical assessments are summarized in a research report and include personalized recommendations provided to families free of charge. Many research studies include our biomarker battery which includes electroencephalography (EEG), eye tracking and, in certain studies, brain imaging using functional magnetic resonance imaging (fMRI).

What are the benefits of participation?

In line with the Seaver Center’s mission, the goal of the clinical research program is to enhance the diagnosis of autism and related disorders, discover biological markers, and to develop and disseminate breakthrough treatments. Research participation is necessary to achieve these long-term objectives.

In addition to helping future generations through medical advancements, as mentioned above, research participants receive results from clinical testing in the form of a research report with recommendations at no cost. These reports may be used to access necessary services both within and outside the school setting.

Who can participate?

Every study has specified enrollment criteria and therefore eligibility varies by study. The Seaver Autism Center has a number of ongoing research studies and encourages you to reach out to the team to discuss studies you or your child may be eligible for.

How do you get involved?

To learn more, call the Seaver Autism Center at 212-241-0961 or email theseavercenter@mssm.edu and one of the clinical research coordinators will provide you with more information.

You may also stay in the know by signing up for the Seaver Autism Center newsletter and by following the Center on social media.

Computational Psychiatry Postdoctoral Fellow Earns NIH Director’s Early Independence Award

Cognitive scientist, computational neuroscientist, well-being researcher—it’s hard to choose only one label to describe Shawn Rhoads, PhD, who recently completed a postdoctoral research fellowship at the Center for Computational Psychiatry at the Mount Sinai Health System. But one title that sticks is recipient of the 2024 National Institute of Health (NIH) Director’s Early Independence Award. The prestigious award, part of the NIH’s High-Risk, High-Reward Research program, supports creative early-career scientists in launching independent research careers.

The award will support Dr. Rhoads as he launches his own lab at Mount Sinai, where he is transitioning to a faculty position as Assistant Professor of Psychiatry, Icahn School of Medicine at Mount Sinai. His research uses modern tools including neuroimaging and computational modeling to approach a modern—and growing—problem. “We’re in the midst of a loneliness epidemic,” Dr. Rhoads explains.

In 2023, the United States Surgeon General released a health advisory on social isolation, citing recent research that found half of U.S. adults report loneliness. Such social disconnection has been linked to a host of negative outcomes, including a greater risk of heart disease, dementia, depression, and early death.

Dr. Rhoads’s research aims to understand the cognitive and neural processes that drive social decision-making—work that could lead to interventions that boost social connection and improve well-being.

A New Way to Study Loneliness  

As an undergrad at the University of Southern California, Dr. Rhoads double majored in psychology and physics. “I was interested in physics as a potential research path, but it was missing that human element,” he says. Fortunately, he found the perfect marriage of his interests and talents in cognitive science and computational modeling. He went on to earn a PhD in the Laboratory on Social and Affective Neuroscience at Georgetown University.

In 2022, he joined Mount Sinai as a postdoctoral fellow in the lab of Xiaosi Gu, PhD, Director of the Center for Computational Psychiatry at the Mount Sinai Health System, and Associate Professor of Psychiatry, and Neuroscience, Icahn School of Medicine at Mount Sinai. It was a perfect fit. “Mount Sinai is one of the only places in the country with an integrated center using computational methods to better understand mental health,” he says.

Working with Dr. Gu, Dr. Rhoads set about designing a project to learn more about loneliness. One response to feeling lonely is to experience a craving or desire for social interaction. “We often think of craving as a negative thing, as in addiction,” he says. “But in this case, craving can be positive if it motivates us to go out into the world to seek connection.”

Some of Dr. Gu’s previous work explored craving in substance use disorders. Now, she and Dr. Rhoads are applying a similar framework to understand how social craving arises, and what happens when that process goes awry. Their model suggests that social craving changes in response to social cues, such as seeing a group of people having fun together. Such social cravings, they predict, are also influenced by expectations and experiences. What happens, for instance, if someone goes to a party expecting a fulfilling social interaction, but doesn’t end up connecting with anyone?

With support from the NIH award, he will use functional brain imaging to understand what happens in people’s brains when they experience social cravings and engage in social interactions. Ultimately, Dr. Rhoads hopes to determine whether those patterns of neural activity can predict negative mental health outcomes such as depression or anxiety.

Seeing Social Decision Making in Real Time

In another line of research, Dr. Rhoads is looking into the brain to see social decision-making in action. In collaboration with researchers, including Ignacio Saez, PhD, Associate Professor of Neuroscience, Neurosurgery, and Neurology, Icahn Mount Sinai, and leader of the invasive electrophysiology core at the Nash Family Center for Advanced Circuit Therapeutics at Mount Sinai, he is working with patients hospitalized while receiving 24/7 intracranial direct brain monitoring as part of their epilepsy treatment.

Dr. Rhoads designed a “gamified” cognitive task for two patients to play together. Each player can earn points working independently, but they have a better chance of high scores if they team up to work with one another. “In order to play together, you need to engage in higher-order social cognitive processes,” he says. For instance, the players have to think multiple steps into the future—not only about their own actions, but also about what they think their partner might do. “The player’s choices are contingent upon their beliefs about what the other person’s strategy is. If I go right, for example, I might assume you’ll go left,” he says.

This ability to consider another person’s mental state is known as theory of mind. By taking direct brain recordings while patients play the game, Dr. Rhoads and his colleagues can apply computational models to make predictions about the players’ beliefs and actions, and see how those predictions play out in the form of brain activity. By collecting brain recordings from two individuals as they interact, the researchers can see social learning and social decision-making in real time. “This is a dynamic system, with changing information as the two players adapt and make choices,” he says.

The ability to imagine another person’s thoughts and perspectives can be helpful, such as when two people are collaborating. But it can also go awry. A person with social anxiety, for example, might ruminate on what they think another person is thinking about them. A person with psychosis might have paranoia about other people being out to get them. “The idea is that we can adapt this model to examine when these cognitive processes can be maladaptive,” Dr. Rhoads says.

A Bright Future for Computational Psychiatry

Though Dr. Rhoads is launching his independent research career, he’s not interested in going it alone. He is eager to collaborate across disciplines, bringing together diverse tools and perspectives to answer questions with implications for individuals and for society.

Meanwhile, he hopes to make computational research accessible to more people. He’s co-director of the Summer Program in Computational Psychiatry Education (SPICE), a research program for high school and college students offered by the Center for Computational Psychiatry. He’s also helping to organize a computational psychiatry workshop for trainees of all levels.

“Computational psychiatry can seem like a daunting field to get into. But we need a diverse and well-represented future of researchers,” he says. “Making these tools more accessible will help us answer some big questions about social behavior and well-being.”

How One Postdoctoral Fellowship Award Recipient Is Helping to Expand Our Knowledge of the Fundamental Mechanisms of Neurodegenerative Diseases

Kristen Whitney, PhD, and John F. Crary, MD, PhD, in the Crary Lab

Kristen Whitney, PhD, whose research in the Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, is aimed at uncovering the earliest changes that occur in the aging brain that are causing cells to die, was named the 2024 recipient of the Robin Chemers Neustein Postdoctoral Fellowship Award.

The award, which encourages and supports female research scientists at Icahn Mount Sinai, was established in 2010 through a generous gift from Robin Chemers Neustein, JD, MBA, a former member of Mount Sinai’s Boards of Trustees. Recipients are senior postdoctoral scientists who intend to complete their training within two years, have demonstrated high-impact accomplishments in biomedical sciences, and exhibit the potential for an independent scientific career.

Dr. Whitney is a postdoctoral fellow in the John F. Crary, MD, PhD, Lab. Dr. Crary is Director of the Mount Sinai Neuropathology Brain Bank and Research CoRE, and Professor of Pathology, Molecular and Cell-Based Medicine, Artificial Intelligence and Human Health, and Neuroscience, Icahn Mount Sinai. His lab is dedicated to uncovering the fundamental mechanisms of neurodegenerative diseases with a focus on the tau protein, the principal component of neurofibrillary tangles seen in Alzheimer’s disease and other disorders, such as progressive supranuclear palsy (PSP).

Says Dr. Crary: “Dr. Whitney is at the forefront of this effort, spearheading innovative research that uses stem cell-derived brain organoids to model PSP. Her work is specifically focused on understanding the role of the integrated stress response in tauopathy, helping to illuminate how cellular stress pathways influence the progression of tau-related diseases. Her contributions are critical in advancing our understanding of PSP, positioning her as a leader in neurodegenerative disease modeling.”

Understanding these mechanisms is a promising path to identifying novel therapeutic strategies and drug targets to delay or cure these devastating diseases.

Dr. Whitney says she first became interested in neurodegenerative diseases in her freshman year of college when she started working as a histology technician in a neuropathology lab. Later, she worked directly with patients as a clinical research coordinator at an Alzheimer’s Disease Research Center. “I observed firsthand the devastating consequences of these diseases,” she says.

In her doctoral work, she investigated a novel drug therapy for traumatic brain injury in preclinical animal models. “My training background in both clinical and basic science research, and working with human samples and model systems, inspired the direction of my postdoctoral work in experimental neuropathology and human patient-derived brain cell model systems,” she says.

“I feel the most powerful way to identify therapeutic strategies for neurodegenerative diseases is to conduct patient-oriented research, focusing on the precious brain donations from our patient populations and developing new personalized, and thus clinically relevant-based model systems, such as our ‘mini-brain’ organoids.”

Dr. Whitney came to Mount Sinai for postdoctoral training specifically to work with Dr. Crary. “His background as a physician-scientist offered a unique opportunity to learn clinical and experimental neuropathology while conducting translational research,” she says.

“Mount Sinai has been an incredible environment to complete my postdoctoral training, particularly in the stem cell, organoid, and neurodegenerative research community,” Dr. Whitney adds. “I have had the opportunity to be mentored by, and collaborate with, some of the top researchers in the field. My projects would never have been possible without all the resources available at Mount Sinai, especially the Dean’s CoREs, such as the Stem Cell Engineering CoRE and the Mount Sinai Neuropathology Brain Bank and Research CoRE.”

“I am beyond thrilled and honored to be selected for this year’s Robin Chemers Neustein Postdoctoral Fellowship Award,” says Dr. Whitney. “Advocacy for women in science and the commitment to dismantling barriers resonate deeply with my values, making the mission of this award especially meaningful for me. I am so grateful to Dr. Crary for his invaluable mentorship throughout the years, and to the selection committee for their recognition and support.”

Pin It on Pinterest